Seminars in Roentgenology
Volume 44, Issue 2 , Pages 111-122 , April 2009

Whole-Body Diffusion-Weighted and Proton Imaging: A Review of This Emerging Technology for Monitoring Metastatic Cancer

  • Michael A. Jacobs, PhD

      Affiliations

    • The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD
    • Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD
    • Corresponding Author InformationAddress reprint requests to Michael A. Jacobs, PhD, Department of Radiology and Oncology, The Johns Hopkins University School of Medicine, Traylor Blg., Room 217, 712 Rutland Avenue, Baltimore, MD 21205
    • ,
  • Li Pan, PhD

      Affiliations

    • Siemens, Corporate Research, Inc, Department of Imaging and Visualization, Baltimore, MD
    • ,
  • Katarzyna J. Macura, MD, PhD

      Affiliations

    • The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD

References 

  1. Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 2008;Nov 25
  2. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2005. CA Cancer J Clin. 2005;55:31–44quiz 55-36
  3. Galasko CS. Skeletal metastases and mammary cancer. Ann R Coll Surg Engl. 1972;50:3–28
  4. Hortobagyi GN. Bone metastases in breast cancer patients. Semin Oncol. 1991;18(suppl 5):11–15
  5. Hamaoka T, Madewell JE, Podoloff DA, et al. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004;22:2942–2953
  6. Vinholes J, Coleman R, Eastell R. Effects of bone metastases on bone metabolism: Implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev. 1996;22:289–331
  7. Wickerham L, Fisher B, Cronin W. The efficacy of bone scanning in the follow-up of patients with operable breast cancer. Breast Cancer Res Treat. 1984;4:303–307
  8. Coleman RE. Monitoring of bone metastases. Eur J Cancer. 1998;34:252–259
  9. Gosfield E, Alavi A, Kneeland B. Comparison of radionuclide bone scans and magnetic resonance imaging in detecting spinal metastases. J Nucl Med. 1993;34:2191–2198
  10. Galasko CS, Doyle FH. The detection of skeletal metastases from mammary cancer (A regional comparison between radiology and scintigraphy). Clin Radiol. 1972;23:295–297
  11. Hayward JL, Carbone PP, Heuson JC, et al. Assessment of response to therapy in advanced breast cancer: A project of the programme on clinical oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer. 1977;39:1289–1294
  12. Stacy GS, Mahal RS, Peabody TD. Staging of Bone tumors: A review with illustrative examples. AJR Am J Roentgenol. 2006;186:967–9762006
  13. Rybak LD, Rosenthal DI. Radiological imaging for the diagnosis of bone metastases. Q J Nucl Med. 2001;45:53–64
  14. Gold RI, Seeger LL, Bassett LW, et al. An integrated approach to the evaluation of metastatic bone disease. Radiol Clin North Am. 1990;28:471–483
  15. Low RN. Magnetic resonance imaging of the abdomen: Applications in the oncology patient. Oncol Williston Park. 2000;14(suppl 3):5–14
  16. Blomqvist L, Torkzad MR. Whole-body imaging with MRI or PET/CT: The future for single-modality imaging in oncology?. JAMA. 2003;290:3248–3249
  17. Schmidt GP, Haug AR, Schoenberg SO, et al. Whole-body MRI and PET-CT in the management of cancer patients. Eur Radiol. 2006;16:1216–1225
  18. Phelps ME. Inaugural article: Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci USA. 2000;97:9226–9233
  19. Phelps ME PET. The merging of biology and imaging into molecular imaging. J Nucl Med. 2000;41:661–681
  20. Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000;41:1369–1379
  21. Gambhir SS, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med. 2001;42:1S–93S
  22. Thie JA. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med. 2004;45:1431–1434
  23. Bydder GM, Young IR. Clinical use of the partial saturation and saturation recovery sequences in MR imaging. J Comput Assist Tomogr. 1985;9:1020–1032
  24. Daffner RH, Lupetin AR, Dash N, et al. MRI in the detection of malignant infiltration of bone marrow. AJR Am J Roentgenol. 1986;146:353–358
  25. Frank JA, Ling A, Patronas NJ, et al. Detection of malignant bone tumors: MR imaging vs scintigraphy. AJR Am J Roentgenol. 1990;155:1043–1048
  26. Fleckenstein JL, Archer BT, Barker BA, et al. Fast short-tau inversion-recovery MR imaging. Radiology. 1991;179:499–504
  27. Bydder GM, Hajnal JV, Young IR. MRI: Use of the inversion recovery pulse sequence. Clin Radiol. 1998;53:159–176
  28. Schmidt GP, Schoenberg SO, Reiser MF, et al. Whole-body MR imaging of bone marrow. Eur J Radiol. 2005;55:33–40
  29. Eustace S, Tello R, DeCarvalho V, et al. A comparison of whole-body turboSTIR MR imaging and planar 99mTc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases. AJR Am J Roentgenol. 1997;169:1655–1661
  30. O'Connell MJ, Hargaden G, Powell T, et al. Whole-body Turbo short Tau inversion recovery MR imaging using a moving tabletop. AJR Am J Roentgenol. 2002;179:866–868
  31. Hargaden G, O'Connell M, Kavanagh E, et al. Current concepts in whole-body imaging using turbo short tau inversion recovery MR imaging. Am J Roentgenol. 2003;180:247–252
  32. Engelhard K, Hollenbach HP, Wohlfart K, et al. Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer. Eur Radiol. 2004;14:99–105
  33. Goris ML, Bretille J. Skeletal scintigraphy for the diagnosis of malignant metastatic disease to the bones. Radiother Oncol. 1985;3:319–329
  34. Flickinger FW, Sanal SM. Bone marrow MRI: Techniques and accuracy for detecting breast cancer metastases. Magn Reson Imaging. 1994;12:829–835
  35. Englander SA, Ulug AM, Brem R, et al. Diffusion imaging of human breast. NMR Biomed. 1997;10:348–352
  36. Johnson KM, Leavitt GD, Kayser HW. Total-body MR imaging in as little as 18 seconds. Radiology. 1997;202:262–267
  37. Steinborn MM, Heuck AF, Tiling R, et al. Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system. J Comput Assist Tomogr. 1999;23:123–129
  38. Barkhausen J, Quick HH, Lauenstein T, et al. Whole-body MR imaging in 30 seconds with real-time true FISP and a continuously rolling table platform: Feasibility study. Radiology. 2001;220:252–256
  39. Daldrup-Link HE, Franzius C, Link TM, et al. Whole-body MR imaging for detection of bone metastases in children and young adults: Comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol. 2001;177:229–236
  40. Frat A, Agildere M, Gencoglu A, et al. Value of whole-body turbo short tau inversion recovery magnetic resonance imaging with panoramic table for detecting bone metastases: Comparison with 99MTc-methylene diphosphonate scintigraphy. J Comput Assist Tomogr. 2006;30:151–156
  41. Johnston C, Brennan S, Ford S, et al. Whole body MR imaging: Applications in oncology. Eur J Surg Oncol. 2006;32:239–246
  42. Li S, Sun F, Jin ZY, et al. Whole-body diffusion-weighted imaging: Technical improvement and preliminary results. J Magn Reson Imaging. 2007;26:1139–1144
  43. Stecco A, Romano G, Negru M, et al. Whole-body diffusion-weighted magnetic resonance imaging in the staging of oncological patients: Comparison with positron emission tomography computed tomography (PET-CT) in a pilot study. Radiol Med. 2008;[epub ahead of print]
  44. Brauck K, Zenge MO, Vogt FM, et al. Feasibility of whole-body MR with T2- and T1-weighted real-time steady-state free precession sequences during continuous table movement to depict metastases. Radiology. 2008;246:910–916
  45. Le Bihan D, Breton E, Lallemand D, et al. MR imaging of intravoxel incoherent motions: Application to diffusion and perfusion in neurologic disorders. Radiology. 1986;161:401–407
  46. Moseley ME, Kucharczyk J, Mintorovitch J, et al. Diffusion-weighted MR imaging of acute stroke: Correlation with T2-weighted and magnetic susceptibility-enhanced MR imaging in cats. AJNR Am J Neuroradiol. 1990;11:423–429
  47. Warach S, Chien D, Li W, et al. Fast magnetic resonance diffusion-weighted imaging of acute human stroke. Neurology. 1992;42:1717–1723
  48. Welch K, Windham J, Knight RA, et al. A model to predict the histopathology of human stroke using diffusion and T2-weighted magnetic resonance imaging. Stroke. 1995;26:1983–1989
  49. Theilmann RJ, Borders R, Trouard TP, et al. Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia. 2004;6:831–837
  50. Mintorovitch J, Moseley M, Chileuitt L, et al. Comparison of diffusion and T2 weighted MRI for the early detection of cerebral ischemia and reperfusion in rats. Magn Reson Med. 1991;18:39–50
  51. Knight RA, Ordidge R, Helpern J, et al. Temporal evolution of ischemic damage in rat brain measured by proton nuclear magnetic resonance imaging. Stroke. 1991;22:802–808
  52. Minematsu K, Li L, Sotak C, et al. Reversible focal ischemic injury demonstrated by diffusion-weighted magnetic resonance imaging in rat brain. Stroke. 1992;23:1304–1311
  53. Szafer A, Zhong J, Gore JC. Theoretical model for water diffusion in tissues. Magn Reson Med. 1995;33:697–712
  54. Le Bihan DJ. Differentiation of benign versus pathologic compression fractures with diffusion-weighted MR imaging: A closer step toward the “holy grail” of tissue characterization?. Radiology. 1998;207:305–307
  55. Cheng KH, Hernandez M. Magnetic resonance diffusion imaging detects structural damage in biological tissues upon hyperthermia. Cancer Res. 1992;52:6066–6073
  56. Chenevert TL, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: An early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst. 2000;92:2029–2036
  57. Guo Y, Cai YQ, Cai ZL, et al. Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging. J Magn Reson Imaging. 2002;16:172–178
  58. Hosseinzadeh K, Schwarz SD. Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue. J Magn Reson Imaging. 2004;20:654–661
  59. Woodhams R, Matsunaga K, Iwabuchi K, et al. Diffusion-weighted imaging of malignant breast tumors: The usefulness of apparent diffusion coefficient (ADC) value and ADC map for the detection of malignant breast tumors and evaluation of cancer extension. J Comput Assist Tomogr. 2005;29:644–649
  60. Jacobs MA, Herskovits EH, Kim HS. Uterine fibroids: Diffusion-weighted MR imaging for monitoring therapy with focused ultrasound surgery—Preliminary study. Radiology. 2005;236:196–203
  61. Kamel IR, Bluemke DA, Eng J, et al. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol. 2006;17:505–512
  62. Manton DJ, Chaturvedi A, Hubbard A, et al. Neoadjuvant chemotherapy in breast cancer: Early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer. 2006;94:427–435
  63. Sinha S, Sinha U. Recent advances in breast MRI and MRS. NMR Biomed. 2008;July 23
  64. Baur A, Stabler A, Bruning R, et al. Diffusion-weighted MR imaging of bone marrow: Differentiation of benign versus pathologic compression fractures. Radiology. 1998;207:349–356
  65. Castillo M, Arbelaez A, Smith JK, et al. Diffusion-weighted MR imaging offers no advantage over routine noncontrast MR imaging in the detection of vertebral metastases. AJNR Am J Neuroradiol. 2000;21:948–953
  66. Herneth AM, Philipp MO, Naude J, et al. Vertebral metastases: Assessment with apparent diffusion coefficient. Radiology. 2002;225:889–894
  67. Takahara T, Imai Y, Yamashita T, et al. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): Technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med. 2004;22:275–282
  68. Herneth AM, Friedrich K, Weidekamm C, et al. Diffusion weighted imaging of bone marrow pathologies. Eur J Radiol. 2005;55:74–83
  69. Murtz P, Krautmacher C, Traber F, et al. Diffusion-weighted whole-body MR imaging with background body signal suppression: A feasibility study at 3.0 Tesla. Eur Radiol. 2007;17:3031–3037
  70. Komori T, Narabayashi I, Matsumura K, et al. 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: Initial experience. Ann Nucl Med. 2007;21:209–215
  71. Koh DM, Takahara T, Imai Y, Collins DJ. Practical aspects of assessing tumors using clinical diffusion-weighted imaging in the body. Magn Reson Med Sci. 2007;6:211–224
  72. Jacobs MA, Pan L, Macura K, et al. Whole body diffusion weighted imaging and ADC mapping for detecting metastatic cancer. Proc Int Soc Mag Reson Med. 2007;15:284
  73. Vilanova JC, Barcelo J. Diffusion-weighted whole-body MR screening. Eur J Radiol. 2008;67:440–447
  74. Ohno Y, Koyama H, Onishi Y, et al. Nonsmall cell lung cancer: Whole-body MR examination for M-stage assessment—Utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology. 2008;248:643–654
  75. Kwee TC, Takahara T, Ochiai R, et al. Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): Features and potential applications in oncology. Eur Radiol. 2008;18:1937–1952
  76. Quick H, Ladd M. Technical requirements for whole-body MRI. Real Whole Body Imaging. (ed 1). New York, NY: McGraw-Hill; 2008;
  77. Bornert P, Aldefeld B. Principles of whole-body continuously-moving-table MRI. J Magn Reson Imaging. 2008;28:1–12
  78. Lauenstein TC, Freudenberg LS, Goehde SC, et al. Whole-body MRI using a rolling table platform for the detection of bone metastases. Eur Radiol. 2002;12:2091–2099
  79. Goyen M. Real Whole Body Imaging. (ed 1). New York, NY: McGraw-Hill; 2008;
  80. Winkelmann R, Bornert P, Dossel O. Ghost artifact removal using a parallel imaging approach. Magn Reson Med. 2005;54:1002–1009
  81. Fautz HP, Honal M, Saueressig U, et al. Artifact reduction in moving-table acquisitions using parallel imaging and multiple averages. Magn Reson Med. 2007;57:226–232
  82. Chou MC, Wang CY, Liu HS, et al. Pseudolesions arising from unfolding artifacts in diffusion imaging with use of parallel acquisition: Origin and remedies. AJNR Am J Neuroradiol. 2007;28:1099–1101
  83. Bammer R. Basic principles of diffusion-weighted imaging. Eur J Radiol. 2003;45:169–184
  84. Jacobs MA. Whole body diffusion weighted imaging screening. MR Cancer Workshop; Int Soc Mag Reson Med. 2008;15:12
  85. Lauenstein TC, Goehde SC, Herborn CU, et al. Whole-body MR imaging: Evaluation of patients for metastases. Radiology. 2004;233:139–148
  86. Antoch G, Vogt FM, Freudenberg LS, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology, in. JAMA. 2003;290:3199–3206
  87. Horvath LJ, Burtness BA, McCarthy S, et al. Total-body Echo-planar MR imaging in the staging of breast cancer: Comparison with conventional methods—Early experience. Radiology. 1999;211:119–128
  88. Walker R, Kessar P, Blanchard R, et al. Turbo STIR magnetic resonance imaging as a whole-body screening tool for metastases in patients with breast carcinoma: Preliminary clinical experience. J Magn Reson Imaging. 2000;11:343–350
  89. El Khouli RH, Jacobs MA, Bluemke DA. Magnetic resonance imaging of the breast. Semin Roentgenol. 2008;43:265–281
  90. Sharma U, Danishad KK, Seenu V, et al. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed. 2009;22:104–113
  91. Hamstra DA, Chenevert TL, Moffat BA, et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci USA. 2005;102:16759–16764
  92. Darge K, Jaramillo D, Siegel MJ. Whole-body MRI in children: Current status and future applications. Eur J Radiol. 2008;68:289–298
  93. Kellenberger CJ, Miller SF, Khan M, et al. Initial experience with FSE STIR whole-body MR imaging for staging lymphoma in children. Eur Radiol. 2004;14:1829–1841
  94. Goo HW, Choi SH, Ghim T, et al. Whole-body MRI of paediatric malignant tumours: Comparison with conventional oncological imaging methods. Pediatr Radiol. 2005;35:766–773
  95. Kumar J, Seith A, Kumar A, et al. Whole-body MR imaging with the use of parallel imaging for detection of skeletal metastases in pediatric patients with small-cell neoplasms: Comparison with skeletal scintigraphy and FDG PET/CT. Pediatr Radiol. 2008;38:953–962
  96. Barcelo J, Vilanova JC, Riera E, et al. Diffusion-weighted whole-body MRI (virtual PET) in screening for osseous metastases [in Spanish]. Radiologia. 2007;49:407–415
  97. Schlemmer HP, Schafer J, Pfannenberg C, et al. Fast whole-body assessment of metastatic disease using a novel magnetic resonance imaging system: Initial experiences. Invest Radiol. 2005;40:64–71

PII: S0037-198X(09)00004-2

doi: 10.1053/j.ro.2009.01.003

Seminars in Roentgenology
Volume 44, Issue 2 , Pages 111-122 , April 2009

Article Tools

* Image Usage & Resolution